Product Description
Abacavir is used along with other medications to treat human immunodeficiency virus (HIV) infection. Abacavir is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV in the blood. Although abacavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people. (Sourced from: https://medlineplus.gov/druginfo/meds/a699012.html)
Mechanisms of Action: NRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: HIV Infections
Phase 1: Glioma|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06428045 |
STARLITE | P1 |
Recruiting |
Glioma |
2029-04-30 |
50% |
2025-06-24 |
Primary Completion Date|Primary Endpoints|Start Date |
ACTRN12621000745842p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Kidney Diseases |
2022-02-28 |
|||
2020-001426-57 |
D3 | P3 |
Active, not recruiting |
HIV Infections |
2026-04-03 |
|||
2013-000783-29 |
2013-000783-29 | P2 |
Completed |
HIV Infections |
2023-04-20 |
67% |
2025-06-09 |
Treatments |
2018-004885-32 |
DOBINeuro | P3 |
Completed |
HIV Infections |
2023-04-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/10/2025 |
News Article |
Precision Medicine Market Size Booms at 16.35% CAGR, Expected to Reach USD 463.11 Billion by 2034 |
|
07/31/2024 |
News Article |
ViiV Healthcare announces positive data demonstrating 2-drug regimen DOVATO is as effective as 3-drug regimen BIKTARVY for maintenance therapy of HIV-1 |
|
07/23/2024 |
News Article |
ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1 |
|
05/14/2024 |
News Article |
HIV Drugs Market Size Expected to Reach USD 49.68 Bn by 2032 |